HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.